Search


Current filters:





Start a new search
Add filters:

Use filters to refine the search results.


Results 1-7 of 7 (Search time: 0.002 seconds).
  • previous
  • 1
  • next
Item hits:
PreviewIssue DateTitleAuthor(s)
2017Is dimension order important when valuing health states using discrete choice experiments including duration?Mulhern, B.; Norman, R.; Lorgelly, P.; Lancsar, E.; Ratcliffe, J.; Brazier, J.; Viney, R.
2017Expression patterns of HENMT1 and PIWIL1 in human testis: implications for transposon expressionHempfling, A.; Lim, S.; Adelson, D.; Evans, J.; O Connor, A.; Qu, Z.; Kliesch, S.; Weidner, W.; O Bryan, M.; Bergmann, M.
2017Design and rationale of the Cardiovascular Health and Text Messaging (CHAT) Study and the CHAT-Diabetes Mellitus (CHAT-DM) Study: two randomised controlled trials of text messaging to improve secondary prevention for coronary heart disease and diabetesHuo, X.; Spatz, E.S.; Ding, Q.; Horak, P.; Zheng, X.; Masters, C.; Zhang, H.; Irwin, M.L.; Yan, X.; Guan, W.; Li, J.; Li, X.; Spertus, J.A.; Masoudi, F.A.; Krumholz, H.M.; Jiang, L.
2017Long-term health status and trajectories of seriously injured patients: a population-based longitudinal studyGabbe, B.J.; Simpson, P.M.; Cameron, P.A.; Ponsford, J.; Lyons, R.A.; Collie, A.; Fitzgerald, M.; Judson, R.; Teague, W.J.; Braaf, S.; Nunn, A.; Ameratunga, S.; Harrison, J.E.; Brohi, K.
2017Developing a set of core outcomes for trials in hemodialysis: an international Delphi surveyEvangelidis, N.; Tong, A.; Manns, B.; Hemmelgarn, B.; Wheeler, D.C.; Tugwell, P.; Crowe, S.; Harris, T.; Van Biesen, W.; Winkelmayer, W.C.; Sautenet, B.; O'Donoghue, D.; Tam-Tham, H.; Youssouf, S.; Mandayam, S.; Ju, A.; Hawley, C.; Pollock, C.; Harris, D.C.; Johnson, D.W.; et al.
2017Modelling predictors of molecular response to frontline imatinib for patients with chronic myeloid leukaemiaBanjar, H.; Ranasinghe, D.; Brown, F.; Adelson, D.; Kroger, T.; Leclercq, T.; White, D.; Hughes, T.; Chaudhri, N.; Speletas, M.
2017Adults with Philadelphia chromosome-like acute lymphoblastic leukemia frequently have IGH-CRLF2 and JAK2 mutations, persistence of minimal residual disease and poor prognosisHerold, T.; Schneider, S.; Metzeler, K.; Neumann, M.; Hartmann, L.; Roberts, K.; Konstandin, N.; Greif, P.; Braeundl, K.; Ksienzyk, B.; Huk, N.; Schneider, I.; Zellmeier, E.; Jurinovic, V.; Mansmann, U.; Hiddemann, W.; Mullighan, C.; Bohlander, S.; Spiekermann, K.; Hoelzer, D.; et al.